Member Info for Theanalyzer

Lex No I don’t know lowest VWAP nor when conversion date was - SYME reported last conversion two weeks after it occurred.

Somebody’s not convinced about this unicorn…

Probably Mercator dumping some stock prior to next conversion aided by RNS news pump.

Next conversion due by end of month but need to shift remaining £300,000 of November first.

Mick2 There is no RNS about purchase of stake in the FinTech Bank because it simply hasn’t happened.

SYME can request extra £2 million in about two weeks time but it is subject to conditions.

My view is that SYME will request the additional £2 million.

If they don’t it could be that an indicator that IM cash flows are close or that SYME were turned down (there are conditions attached to drawdown).

Something for bulls and bears to argue over other than IFRS 15.

Tradeflow isn’t a big revenue generator yet. In first six months it generated under £300,000 which isn’t in SYME numbers. It may be larger say £500,000 to £600,000 in second half based on first half run rate plus uplift for $40 million of additional funding. Nowhere large enough to offset running costs hence loan note conversion.

Working capital my arse it’s a death spiral conversion to fund ongoing losses to keep the lights on.

Looks like the bears on site was correct about how strapped SYME is for cash.

Gives the dwindling band of bulls another opportunity to average down and buy more cheap golden tickets at bargain prices.

Don’t worry though it’s all good it’s SYME

It’s SYME it’s all good.

Thank you AZ

Nobody’s it’s true that the interim accounts for 2021 don’t include Tradeflow as it was acquired in July 2021 but the year end 2021. forecast does include Tradeflow. We also know that Tradeflow revenue for six months was only £272,000 ( not in SYME figures but disclosed by SYME) so don’t get too excited about Tradeflow just yet. It might account for £600,000 in financial year 2021 (same amount as first half in 2nd half plus. 1.5% of 1/2 year of new $40 million funding.

In any case I suspect Tradeflow is loss making at present due to lack of scale.

Kchappers

The bull case is the market potential is huge, the rewards for. a Fintech platform if it could successfully open up such a large new market would be also potentially huge.

Banks make a lot of money from mortgage, credit card, trade receivables and other asset type of securitisations .

SYME is at present a bet for me on whether AZ can an IM done and then repeat that process and get first mover advantage in a new sector.

Guy Hands became a multi billionaire by monetisation of new assets such as pub chains etc.

This is why I take an interest in SYME.

Personally as a shareholder in Opti and Skin I would have preferred a dividend in specie but overall it widens Skin shareholder base and reduces Opti sell down risk and Opti has some more cash as it get closer to profitability, so happy to hold both.

Usual desperate bulls coming out with usual insults to try and rebut hard facts.

The reality is that other than paying over 10 times revenue plus additional earnout for Tradeflow if it hits future revenue targets, what else has AZ achieved in concrete terms since March 2020 when SYME undertook it’s IPO? Like a single named actual client or funders beyond Negma and Mercator for the core business?

There are a lot of potential deals that simply fade away, whatever ever happened to Stormharbour?

Jimmy London I am curious what do you mean by Financial. Independence?

No mortgage, income from savings or rental properties or pension so you do not need to work again or something else?
.
I suspect it depends on what lifestyle you have or want to have and how money much you need to support that lifestyle.

For some people it could be £500,000 others 1 million, others, a lot less.

I have posted on forum basically saying why is the dictator trying to stop you from trying the product.

I think word of mouth from users will drive support over time but that will take a few weeks at minimum

So for now I will sit back and relax.

Angusscott
AZ didn’t invest millions into SYME he was given a lot of shares as part of RTO. Those shares may be worth millions but he did not put that much cash to be awarded those shares. Second I believe he has effectively sold many of the shares via structured loan arrangements.

AZ is a salesman and a natural optimist but not so good at getting stuff done.

Yes SYME is a start up but it’s credibility is being severe damaged by constant delays in IM and endless excuses for delays. Where was Stormharbour in latest update? Where was extension to Fintech bank deal?

Jim Coyle has got himself into a very tricky situation. He can’t realistically fire AZ because SYME is his baby and there is no deputy. The Group has major cashflow problems because revenue just moved out further and all the new staff will have increased cash burn further, it was £1.5 million at interim stage. Using Mercator share repayment option to conserve cash will further depress share price but it looks the only option at present time.

Year end accounts won’t make for pretty reading at this rate.

Unless you are Lseking a well paid train driver it isn’t all good.

Jam Butty

If by HGL you mean Hargreaves Lansdown that is all PI money. HL don’t invest shareholders funds in individual shares as you can see if you at HL own accounts.

PI have been buying while AZ and DW , Negma have all been selling.

The new CEO looks to be transforming the group rapidly but it’s still all jam tomorrow at present.

The inability of bulls of this stock to understand the interim accounts published is quite shocking.

Profits were only £94,000 and these were only achieved after booking a huge profit of over £900,000 on disposal of Market Access, so ongoing business remains loss making due to size of administrative expenses.

The revenue still includes the lottery and legal services division because they were still owned by Tintra for first half.

I will continue to monitor share because I do like the pace of change under new CEO and intended strategy makes sense but I won’t be buying just yet, I will see what financial position is after the upcoming placing.

Farris just added post myself about new treatment and cited AxisBiotix.com website.

Probably will be proper launch tomorrow but hopefully a few comments may well help the debate.

Belgrano
Thanks for comment. The pre registration process was a great way to build and gauge demand for the product and your comment supports wisdom of SBTX using an established supplier who can scale up production rapidly.

I wonder how long it will take before SBTX release order or revenue data will it be in a month’s time? it is clearly going to be a very price sensitive number.

Belgrano The Cenkos note showing revenue showed how large revenues might be just on U.K. market and we know that US market is 5 times larger than U.K.

.As I said other day, this looks to be a company with a supply challenge as opposed to a demand challenge. Agree with your view that a company with such characteristics should be on a high PE multiple.

Once revenue and profits flow then company will start to attract IIs

It effectively a med tech company.

Not selling a bean.